ReviewFrontiers in cellular and infection microbiology2022
PLGA-Based Nanoplatforms in Drug Delivery for Inhibition and Destruction of Microbial Biofilm.
Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antibiotic Nanoparticles-Loaded Wound Dressings AgainstInternational journal of nanomedicine · 2024Pooled it
- Harnessing gasotransmitters for orthopaedic infection therapy: Mechanisms and advanced delivery platforms.Bioactive materials · 2027Review
- Biofilm-mediated antibiotic tolerance in bacterial pathogens: Integrated molecular networks and novel therapeutic avenues.Virulence · 2026Review
- Current and emerging antibacterial strategies for periprosthetic joint infection: An overview.Bioactive materials · 2026Review
- Pharmaceutical innovation in advanced nanomedicine for the treatment of hypervirulent and multidrug-resistant Klebsiella pneumoniae infections.Archives of microbiology · 2026Review
- Exploring the antibacterial and antibiofilm potential of 1,8-cineole against Escherichia coli through in vitro, gene expression, and in silico analyses.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Exploitation of cholesterol-dependent cytolysins for targeted biosensing and therapeutic systems.Drug delivery and translational research · 2026Review
- Nanotechnology revolutionizing antimicrobial therapy for superbug infections.Discover nano · 2026Review
- RSM optimization of Tetracycline-loaded PLGA nanoparticles in chitosan/HPMC hydrogels for sustained antibacterial delivery.Scientific reports · 2026Article
- Nanoparticle-Based Strategies to Combat Multidrug-Resistant Bacteria: Mechanisms, Applications, and Future Perspectives.MicrobiologyOpen · 2026Review
- Nanomedicine Strategies Against Biofilm-Associated Infections: Advances, Challenges, and Translational Barriers.MicrobiologyOpen · 2026Review
- Natural Compound-Loaded PLGA Nanocarriers for Infected Wound Management: A Review.International journal of nanomedicine · 2026Review
- Nano-enabled disruption of bacterial virulence and communication in plant pathosystems: emerging strategies for sustainable disease management.Frontiers in plant science · 2026Review
- Prophylactic adjuvant therapy for postoperative recurrence of urethral stricture: a narrative review.Translational andrology and urology · 2025Review
- Nanoparticle-mediated approaches to combat antibiotic resistance: a comprehensive review on current progress, mechanisms, and future perspectives.RSC advances · 2025Review
- Updates on therapeutic targeting of diguanylate cyclase for addressing bacterial infections: A comprehensive review.World journal of microbiology & biotechnology · 2025Review
- Antimicrobial Nanoparticles Against Superbugs: Mechanistic Insights, Biomedical Applications, and Translational Frontiers.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Multiple Strategies for the Application of Medicinal Plant-Derived Bioactive Compounds in Controlling Microbial Biofilm and Virulence Properties.Antibiotics (Basel, Switzerland) · 2025Review
- Enhanced Tumor Targeting with Midazolam-Loaded PLGA Nanoparticles: An In Vivo Analysis of Safety and Efficacy.Medical science monitor basic research · 2025Article
- Biofilm Resilience: Molecular Mechanisms Driving Antibiotic Resistance in Clinical Contexts.Biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The biofilm community of microorganisms has been identified as the dominant mode of microbial growth in nature and a common characteristic of different microorganisms such as Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis. The biofilm structure helps in the protection from environmental threats including host immune system and antimicrobial agents. Thus, the biofilm community has led to a higher prevalence of multidrug-resistant (MDR) strains in recent years. In this regard, the use of a new class of antibiotics, natural compounds, and anti-biofilm enzymes has been considered for the destruction of the microbial biofilm. However, different drawbacks such as low penetration, high susceptibility to degradation, instability, and poor solubility in aqueous solutions limit the use of anti-biofilm agents (ABAs) in a clinical setting. As such, recent studies have been using poly lactic-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.